Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer.
Breast cancer (BC) is the most common malignancy among women in Canada. Adjuvant treatment in early BC can reduce the risk of BC recurrence. Historically, the decision for adjuvant chemotherapy for early BC was made only based on clinical and tumour characteristics. In recent years, there has been a...
| Publicado en: | Current Oncology Vol. 29; no. 7; pp. 5139 - 5150 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jul2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=158209880&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 158209880 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jul2022 vid: 29 iid: 7 pid: 97109 pub: MDPI artinfo: ui: 158209880 10.3390/curroncol29070407 158209880 ppf: 5139 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer. aug: au: Pauls, Mehrnoosh Chia, Stephen affil: Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada sug: ab: Breast cancer (BC) is the most common malignancy among women in Canada. Adjuvant treatment in early BC can reduce the risk of BC recurrence. Historically, the decision for adjuvant chemotherapy for early BC was made only based on clinical and tumour characteristics. In recent years, there has been an effort toward developing genomic assays as a predictive and prognostic tool to improve precision in estimating disease recurrence, sensitivity to systemic treatment and ultimately with clinical utility for guidance regarding adjuvant systemic treatment(s). There are various commercial genomic tests available for early-stage ER+/HER-2 negative BC. This paper will review the Oncotype DX 21-gene Recurrence Score (RS), MammaPrint, EndoPredict, Prosigna®, and Breast Cancer Index (BCI) genomic assays. We will also focus on these genomic assays' clinical application and utility in node-positive early-stage BC based on the most recent evidence and guidance recommendations. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|